Raymond James Maintains Strong Buy on Medical Properties Trust, Lowers Price Target to $20
Raymond James analyst Jonathan Hughes maintains Medical Properties Trust (NYSE:MPW) with a Strong Buy and lowers the price target from $24 to $20.
Raymond James Maintains Outperform on MSCI, Lowers Price Target to $493
Raymond James analyst Patrick O'Shaughnessy maintains MSCI (NYSE:MSCI) with a Outperform and lowers the price target from $515 to $493.
Barclays Maintains Equal-Weight on Regency Centers, Lowers Price Target to $69
Barclays analyst Anthony Powell maintains Regency Centers (NASDAQ:REG) with a Equal-Weight and lowers the price target from $78 to $69.
Barclays Maintains Overweight on Kite Realty Gr Trust, Lowers Price Target to $28
Barclays analyst Anthony Powell maintains Kite Realty Gr Trust (NYSE:KRG) with a Overweight and lowers the price target from $29 to $28.
Barclays Maintains Overweight on Kimco Realty, Lowers Price Target to $26
Barclays analyst Anthony Powell maintains Kimco Realty (NYSE:KIM) with a Overweight and lowers the price target from $30 to $26.
Barclays Maintains Overweight on Federal Realty Investment, Lowers Price Target to $122
Barclays analyst Anthony Powell maintains Federal Realty Investment (NYSE:FRT) with a Overweight and lowers the price target from $142 to $122.
UBS Maintains Neutral on Netflix, Lowers Price Target to $198
UBS analyst John Hodulik maintains Netflix (NASDAQ:NFLX) with a Neutral and lowers the price target from $355 to $198.
Citigroup Maintains Neutral on Conagra Brands, Lowers Price Target to $35
Citigroup analyst Wendy Nicholson maintains Conagra Brands (NYSE:CAG) with a Neutral and lowers the price target from $37 to $35.
Barclays Maintains Overweight on Hess, Lowers Price Target to $149
Barclays analyst Jeanine Wai maintains Hess (NYSE:HES) with a Overweight and lowers the price target from $153 to $149.
SVB Leerink Maintains Outperform on Tenet Healthcare, Lowers Price Target to $68
SVB Leerink analyst Whit Mayo maintains Tenet Healthcare (NYSE:THC) with a Outperform and lowers the price target from $110 to $68.